Precigen Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
Precigen (NASDAQ:PGEN) has been granted FDA orphan drug exclusivity for its treatment, PAPZIMEOS, which is used to treat adult recurrent respiratory papillomatosis. This designation provides market protection until 2032 and highlights the therapy's sustained effectiveness in reducing surgical interventions.
Topics: biopharmaceutical gene therapy orphan drug designation